Table 1.

SLC26A2 overexpression is correlated with worsened disease

Tumor type	Differential expression	Fold change	P	Dataset
Breast	Metastatic event at 1 year vs. no event at 1 year	2.282	9.88E−10	Minn Breast 2
Breast	Metastatic site vs. primary site	2.485	0.005	Weigelt Breast
Brain	Glioblastoma dead at 5 years vs. alive	2.531	6.02E−4	Nutt Brain
Lung	Lung adenocarcioma - advanced N stage	2.125	0.001	Beer Lung
Breast	Ductal breast carcinoma- ERBB2/ER/PR negative vs. positive	5.313	5.75E−6	Richardson Breast 2
Breast	Invasive ductal breast carcinoma stroma vs. normal	2.214	8.23E−5	Karnoub Breast
Colon	Colon adenocarcinoma dead at 1 year vs. alive	2.695	0.003	TCGA Colorectal
Brain	Glioblastoma vs. normal	2.002	6.38E−18	Sun Brain
Lymphoma	Anaplastic large cell lymphoma vs. normal	5.641	2.79E−8	Piccaluga Lymphoma
Lymphoma	Angioimmunoblastiv T-cell lymphoma vs. normal	3.689	5.32E−8	Piccaluga Lymphoma
Lymphoma	Unspecified peripheral T-cell lymphoma vs. normal	3.489	6.22E−13	Piccaluga Lymphoma
Ovarian	Ovarian clear cell adenocarcinoma vs. normal	2.353	8.41E−4	Lu Ovarain
Prostate	Prostatic intraepithelial neoplasia epithelia vs. normal	3.646	1.53E−4	Tomlins Prostate
Liver	Hepatocellular carcinoma vs. normal	3.239	5.64E−5	Wurmbach Liver
Renal	Nonhereditary clear cell renal carcinoma vs. normal	2.371	6.45E−7	Beroukhim Renal
Melanoma	Skin basal cell carcinoma vs. normal	2.337	2.15E−4	Riker Melanoma
Melanoma	Metastaic site vs. primary site	2.079	5.01E−5	Xu Melanoma
Renal	Renal Wilms tumor vs. normal	2.210	0.004	Yusenko Renal
Brain	Glioblastoma vs. normal	2.328	5.46E−5	Murat Brain
Brain	Anaplastic oligodendroglioma vs. normal	2.384	1.86E−5	French Brain